We are live on ! Find out more
INMB icon

INmune Bio
INMB

41 hedge funds and large institutions have $30.6M invested in INmune Bio in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% more capital invested

Capital invested by funds: $15.5M → $30.6M (+$15.1M)

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

24% more funds holding

Funds holding: 33 → 41 (+8)

2.9% more ownership

Funds ownership: 8.75% → 11.65% (+2.9%)

7% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $972K

Holders
41
Holders Change
+8
Holders Change %
+24.24%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
7
Reduced
5
Closed
10
Calls
$1.04M
Puts
$972K
Net Calls
+$64K
Net Calls Change
+$64K

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$2.18M
2
EGI
EAM Global Investors
California
+$1.57M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$889K
4
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
+$773K
5
Citadel Advisors
Citadel Advisors
Florida
+$755K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$1.17M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$536K
3
Millennium Management
Millennium Management
New York
-$499K
4
BlackRock
BlackRock
New York
-$481K
5
HF
HRT Financial
New York
-$262K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$6.66M +$889K +65,948 +21%
BlackRock
2
BlackRock
New York
$3.23M -$481K -35,724 -16%
EI
3
EAM Investors
California
$2.84M +$2.18M +161,793 New
IC
4
Ikarian Capital
Texas
$2.58M -$1.17M -86,693 -37%
EGI
5
EAM Global Investors
California
$2.05M +$1.57M +116,809 New
Deutsche Bank
6
Deutsche Bank
Germany
$1.86M – – –
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$1.33M +$575K +42,642 +129%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.3M +$175K +12,957 +21%
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$1.17M +$12.3K +910 +1%
Janney Montgomery Scott
10
Janney Montgomery Scott
Pennsylvania
$1.01M +$773K +57,340 New
Citadel Advisors
11
Citadel Advisors
Florida
$985K +$755K +56,056 New
ACM
12
Altium Capital Management
New York
$918K +$704K +52,257 New
State Street
13
State Street
Massachusetts
$612K +$469K +34,816 New
Belvedere Trading
14
Belvedere Trading
Illinois
$588K +$377K +27,968 New
Osaic Holdings
15
Osaic Holdings
Arizona
$479K +$260K +19,280 +242%
BFM
16
Boothbay Fund Management
New York
$424K -$107K -7,912 -25%
FAIM
17
Financial Advocates Investment Management
Washington
$345K – – –
AA
18
ALPS Advisors
Colorado
$345K +$265K +19,663 New
Northern Trust
19
Northern Trust
Illinois
$245K – – –
FA
20
Fermata Advisors
California
$206K +$158K +11,750 New
Morgan Stanley
21
Morgan Stanley
New York
$203K +$114K +8,450 +273%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$194K – – –
VF
23
Virtu Financial
New York
$185K +$142K +10,530 New
MSA
24
Marino Stram & Associates
Massachusetts
$182K +$140K +10,369 New
YWP
25
YorkBridge Wealth Partners
New York
$182K +$140K +10,369 New
1
2 3

INMB Hedge Fund Activity: Q2 2021 in Review

41 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2021, worth a combined $30.6M — up 98% from $15.5M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new INMB positions and 10 closed out — a net gain of 8 holders — while 7 added to existing stakes and 5 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $2.18M. The largest seller was Ikarian Capital, cutting an estimated $1.17M.

  • 41 institutional investors held INmune Bio (INMB) as of Q2 2021, up from 33 in Q1 2021.
  • Funds reported $30.6M of INmune Bio stock for Q2 2021, up 98% quarter-over-quarter.
  • 18 funds opened new INmune Bio positions in Q2 2021 and 10 closed out, a net change of +8 holders.
  • The largest INmune Bio buyer in Q2 2021 was EAM Investors, an estimated $2.18M added.
  • The largest INmune Bio seller in Q2 2021 was Ikarian Capital, an estimated $1.17M sold.

Based on aggregated 13F filings for Q2 2021.